- Home
- LYT vs MBRX Comparison
LYT vs MBRX Comparison
Compare LYT & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYT
- MBRX
- Stock Information
- Founded
- LYT 2020
- MBRX 2015
- Country
- LYT India
- MBRX United States
- Employees
- LYT N/A
- MBRX N/A
- Industry
- LYT EDP Services
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- LYT Technology
- MBRX Health Care
- Exchange
- LYT Nasdaq
- MBRX Nasdaq
- Market Cap
- LYT 1.8M
- MBRX 1.4M
- IPO Year
- LYT 2022
- MBRX 2016
- Fundamental
- Price
- LYT $0.27
- MBRX $1.28
- Analyst Decision
- LYT
- MBRX Strong Buy
- Analyst Count
- LYT 0
- MBRX 2
- Target Price
- LYT N/A
- MBRX $24.00
- AVG Volume (30 Days)
- LYT 12.6M
- MBRX 13.3M
- Earning Date
- LYT 04-09-2025
- MBRX 03-21-2025
- Dividend Yield
- LYT N/A
- MBRX N/A
- EPS Growth
- LYT N/A
- MBRX N/A
- EPS
- LYT 0.30
- MBRX N/A
- Revenue
- LYT $21,363,775.00
- MBRX N/A
- Revenue This Year
- LYT N/A
- MBRX N/A
- Revenue Next Year
- LYT N/A
- MBRX N/A
- P/E Ratio
- LYT $0.90
- MBRX N/A
- Revenue Growth
- LYT 12.39
- MBRX N/A
- 52 Week Low
- LYT $0.22
- MBRX $0.40
- 52 Week High
- LYT $18.62
- MBRX $6.24
- Technical
- Relative Strength Index (RSI)
- LYT 28.93
- MBRX 46.92
- Support Level
- LYT $0.22
- MBRX $1.55
- Resistance Level
- LYT $0.54
- MBRX $2.22
- Average True Range (ATR)
- LYT 0.05
- MBRX 0.50
- MACD
- LYT 0.01
- MBRX 0.08
- Stochastic Oscillator
- LYT 12.20
- MBRX 27.12
About LYT Lytus Technologies Holdings PTV. Ltd.
Lytus Technologies Holdings Pvt Ltd is a platform services company providing content streaming/telecasting services to users located all across India. Its scope of business also covers telemedicine services with local assistance through local Health Centers. Through its platform, the customers are well connected via customer premises equipment (CPE) devices/set-top boxes (STBs) and have access to multi-dimensional services including telemedicine service.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.